GSK is submitting data to the FDA regarding potential expansion of its drug indications.
2 reports, 2 independent
Updated Sep 24
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
GSK is submitting data to the FDA regarding potential expansion of its drug indications.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.Also in this story
- GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.
- Harmony, IDEAYA, and Hoffmann-La Roche partnered to study combination therapy for pancreatic cancer using machine learning.
The entities involved
- FDA
-
GSK
British multinational pharmaceutical and biotechnology company
-
GSK
British multinational pharmaceutical and biotechnology company
Related events
- BioTech generated encouraging early data for MASH and POTS, and expects an FDA decision regarding cemdisiran next month.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- A company submitted study data supporting a PMA submission to the FDA.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Adam Craig reported positive results that could support FDA approval for a treatment.